Pfizer Inc. closed 28.57% short of its 52-week high of $31.54, which the company reached on July 30th.

We recently published a list of Jim Cramer’s Thoughts on These 5 Stocks. In this article, we are going to take a look at ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

In summary, income-focused investors may find Pfizer stock an attractive option for making a steady income of $100 per month ...

Cantor Fitzgerald analyst Carter Gould initiated coverage of Pfizer (PFE) with a Neutral rating and $24 price target Pfizer made “concrete ...

Vantage with Palki Sharma | N18G Pfizer has halted development of its potential weight loss pill after a patient suffered ...

Pfizer has been paying dividends for 35 years and raising them for 14 years. Read more to see whether PFE stock is a buy.

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...